

Supplementary Information


Protection against proteolysis of a cell targeting peptide on gold nanostructures

Francesca Biscaglia, Isabella Caligiuri, Giorgio Ripani, Flavio Rizzolio, Antonio Palleschi, Moreno Meneghetti and Marina Gobbo

Table of Contents:

UV-vis and SERRS spectra of nanostructures	pag. S2
TEM images of nanostructures	pag. S3
DLS, ζ -potential and peptide content of nanostructures	pag. S3
HPLC of degradation products of GE11 in human serum	pag. S4
HPLC of the trypsin digestion of K ₃ G ₂ -GE11 and Au@PEG-K ₃ G ₂ -GE11	pag. S5
HPLC of the chymotrypsin digestion of GE11 and targeted nanostructures	pag. S6
HPLC and MS characterization of peptides GE11 and K ₃ G ₂ -GE11	pag. S7
Expression of the EGFR protein in SW480 and SW620 cells	pag. S8

A : AuNP@C-GE11



B: AuNP@PEG-K₃G₂-GE11




Figure S1. Characterization of nanostructures. Au@C-GE11 (A) and Au@PEG-K₃G₂-GE11 (B). On the left, evolution of the extinction spectra during the assembling steps of the nanostructures: naked gold nanoparticles (black line), after aggregation and labelling with the SERRS reporter (red line) and conjugation of peptide ligands (blue line). On the right, SERRS spectra of the final nanostructures.




Figure S2. TEM images of Au@C-GE11 (left) and Au@PEG-K₃G₂-GE11 (right) nanostructures.

Table S1. Characterization of the targeted nanostructures.

Nanostructure	Peptides per nanoparticle	Hydrodynamic diameter (nm)	ζ-potential (mV)
AuNP@C-GE11	10000	70 ±8	-14 ±1
AuNP@PEG-K ₃ G ₂ -GE11	2200	100 ±6	14 ±2




Figure S3. HPLC chromatograms of degradation products of GE11 in 20% human serum. All samples were treated with TCA and centrifuged before injection in HPLC. From the bottom: black line: 20% aq serum; red line: peptide without serum; other lines: aliquots (100 μ L) withdrawn from the incubation solution at the indicated time.

Column: Vydac 218TP54 (250x4.6 mm, 5 μ m, flow rate at 1 ml/min). The elution was carried out with binary gradients combining mobile phases A (aqueous 0.1% TFA) and B (acetonitrile 0.1%TFA). Elution conditions: isocratic 5 % B in 5 min; linear gradient 5-50 % B in 30 min.



A**B**

Figure S4. HPLC chromatograms of aliquots withdrawn from the digestion of the peptide or the nanostructures with trypsin: K_3G_2 -GE11 (A); AuNP@PEG- K_3G_2 -GE11 (B). Elution conditions as in Figure S3.






A**B****C**

Figure S5. HPLC chromatograms of aliquots withdrawn from the digestion of the peptide or the nanostructures with chymotrypsin: GE11 peptide (**A**); AuNP@C-GE11 (**B**); AuNP@PEG-K₃G₂-GE11 (**C**). Elution conditions as in Figure S3.

A : GE11



B: K₃G₂-GE11





Figure S6. HPLC and ESI-MS spectra of synthesized peptides: GE11 (A) and K₃G₂-GE11 (B). Analytical HPLC separations were performed on a Vydac 218TP54 column (250 x 4.6 mm, 5 μ m, flow rate at 1 ml/min). Elution conditions as in Figure S3.




Figure S7: Western blot analysis of EGFR expression in SW480 and SW620 cell lines. The amount of loaded proteins was detected with the ponceau red staining (p.red).